

A multi-center observational study testing the discontinuation of tyrosine kinase inhibitors in patients with chronic phase chronic myeloid leukemia



Patients with chronic phase chronic myeloid leukemia who discontinued tyrosine kinase inhibitors (TKIs) in deep molecular response (DMR)

- Median age at diagnosis: 49 years (IQR 38-60)
- Median age at discontinuation: 59 years (IQR 48-70)



	ALL	Imatinib	2 nd generation TKIs	
• Median duration of treatment with any TKI (months)	87 (IQR 57;117)	96 (IQR 62-120)	73 (IQR 51-98)	p=0.002
• Median duration of DMR (months)	46 (IQR 30;73)	53 (IQR 33-82)	36 (IQR 25.46)	p<0.001
Primary endpoint				
• Treatment-free remission rate (TFR) at 12 months	69% (95%CI 64-75)	68% (95%CI 62-74)	73% (95%CI 64-83)	
	34 months (IQR 24-53)	42 months (IQR 26-56)	26 months (IQR 21-34)	
Secondary endpoints				
• TFR status at median follow-up	62% (95%CI 56-68)	60% (95%CI 54-67)	67% (95%CI 57-78)	

Discontinuation of tyrosine kinase inhibitors is safe and effective in clinical practice